Non-calcified plaque volume assessed by coronary computed tomographic angiography: prognostic significance, reproducibility, and temporal progression.
文献摘要
Aims Coronary artery disease remains the leading cause of cardiovascular mortality worldwide, with a substantial proportion of acute coronary events arising from rupture of non-calcified, lipid-rich plaques not detected by conventional coronary artery calcium scoring. Coronary computed tomographic angiography (CCTA) enables direct visualization and volumetric quantification of non-calcified plaque volume (NCPV), capturing a biologically active component of coronary atherosclerosis. No comprehensive synthesis of NCPV's prognostic significance, measurement reproducibility, and pharmacological modifiability has been published. This review addresses that gap. Methods and results We conducted a narrative review of published literature through March 2025 using PubMed, synthesizing evidence from multicentre trials and registry analyses. Studies including SCOT-HEART, ICONIC, CONFIRM, and PARADIGM demonstrate that NCPV is associated with major adverse cardiovascular events independent of coronary artery calcium score, cardiovascular risk scores, and stenosis severity. Low-attenuation plaque burden represents one of the strongest predictors of myocardial infarction. Non-obstructive high-risk plaques confer risk comparable to obstructive lesions without high-risk features. Sex-related differences in plaque composition are clinically relevant, with women demonstrating lower fibrous and fibrofatty plaque volumes than men. Artificial intelligence-based quantitative CCTA has improved reproducibility, with interobserver variability below 3%. Serial imaging demonstrates that NCPV is modifiable with intensive lipid-lowering therapy. Conclusion NCPV assessed by CCTA represents a reproducible and prognostically relevant measure of coronary atherosclerosis that is responsive to therapy. Recent regulatory interest, including submission of a Biomarker Qualification Program Letter of Intent to the US Food and Drug Administration, highlights its potential role as a biomarker for clinical trial enrichment.